Cha Biotech said on the 28th it will work with Miltenyi Biotec, a global cell and gene therapy company, to develop an allogeneic chimeric antigen receptor-expressing natural killer cell (CAR-NK) therapy.
Under the collaboration, Miltenyi Biotec will produce lentiviral vectors and supply them to Cha Biotech. The company said Miltenyi brings expertise including its BaEV platform, designed to improve gene-delivery efficiency while lowering manufacturing costs. The BaEV platform targets ASCT1 and ASCT2 receptors expressed on NK cells to boost gene transfer efficiency.
Cha Biotech plans to use the vectors to develop a CAR-NK-based anticancer cell therapy, CHACAR-NK-201. Based on its in-house NK cell culture technology, the company said it is expanding research in solid tumors including liver cancer, glioblastoma and triple-negative breast cancer.
A Cha Biotech official said CAR-NK therapies are viewed as next-generation immune cell treatments because they can be mass-produced using NK cells from healthy donors, offering advantages in accessibility and cost compared with CAR-T therapies that require patient-specific manufacturing.
Separately, Cha Biotech said it is also working with Miltenyi Biotec Korea to develop an automated process for mass production of allogeneic CAR-NK therapies and to strengthen manufacturing capabilities that meet global standards.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.